Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention

References

• Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008;197(Suppl 2):S58–60.
   PubMed Web of Science ®Google Scholar
• Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc. 2016;9:447–454.
   PubMed Web of Science ®Google Scholar
• Johnson RW, Alvarez-Pasquin M-J, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3:109–120.
   PubMedGoogle Scholar
• Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197:825–835.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200:1068–1077.
   PubMed Web of Science ®Google Scholar
• Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51:197–213.
   PubMed Web of Science ®Google Scholar
• Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007;211:144–156.
   PubMed Web of Science ®Google Scholar
• Patterson-Bartlett J, Levin MJ, Lang N, et al. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine. 2007;25:7087–7093.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81:928–930.
   PubMed Web of Science ®Google Scholar
• Cohen JI, Straus SE, Arvin AM. Varicella-zoster virus: Replication, pathogenesis, and management. In: Knipe DM, Howley PM, editors. Fields Virology. 5th ed. Philadelphia, PA: Lippincott-Williams & Wilkins; 2007.
   Google Scholar
• Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68:2328–2337.
   PubMed Web of Science ®Google Scholar
• Habel LA, Ray GT, Silverberg MJ, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:82–90.
   PubMed Web of Science ®Google Scholar
• Weitzman D, Shavit O, Stein M, et al. A population based study of the epidemiology of herpes zoster and its complications. J Infect. 2013;67:463–469.
   PubMed Web of Science ®Google Scholar
• Tran TN, Ray GT, Horberg MA, et al. Complications of herpes zoster in cancer patients. Scand J Infect Dis. 2014;46:528–532.
   PubMed Web of Science ®Google Scholar
• Gater A, Uhart M, McCool R, et al. The humanistic, economic and societal burden of herpes zoster in Europe: a critical review. BMC Public Health. 2015;15:193.
   PubMed Web of Science ®Google Scholar
• Varghese L, Standaert B, Olivieri A, et al. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17:30.
   PubMed Web of Science ®Google Scholar
• Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(Suppl 1):S111–118.
   PubMedGoogle Scholar
• Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clinic Proc. 2007;82:1341–1349.
   PubMed Web of Science ®Google Scholar
• Le P, Sabella C, Rothberg MB. Preventing herpes zoster through vaccination: new developments. Cleve Clin J Med. 2017;84:359–366.
   PubMed Web of Science ®Google Scholar
• Weinmann S, Chun C, Schmid DS, et al. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005–2009. J Infect Dis. 2013;208:1859–1868.
   PubMed Web of Science ®Google Scholar
• Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866.
   PubMed Web of Science ®Google Scholar
• Werner RN, Nikkels AF, Marinović B, et al. European consensus-based (s2k) guideline on the management of herpes zoster – guided by the European Dermatology Forum (edf) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 2: treatment. J Eur Acad Dermatol Venereol. 2017;31:20–29.
   PubMed Web of Science ®Google Scholar
• Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356–363.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003;188:1336–1344.
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–2284.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55:1320–1328.
   PubMed Web of Science ®Google Scholar
• ZOSTAVAX® (Zoster Vaccine Live). Product information. [ cited 2017 Apr 19]. Available from https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM132831.pdf.
   Google Scholar
• Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–1032.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–2096.
   PubMed Web of Science ®Google Scholar
• Varivax. Prescribing information. [ cited 2017 June 01]. Available from https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142813.pdf.
   Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54:922–928.
   PubMed Web of Science ®Google Scholar
• Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900–909.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older. Clin Infect Dis. 2017;64:785–793.
   PubMed Web of Science ®Google Scholar
• Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10:e1001420.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults aged >/=60 years. J Infect Dis. 2016;213:1872–1875.
   PubMed Web of Science ®Google Scholar
• Baxter R, Bartlett J, Fireman B, et al. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol. 2017;187:161–169.
   Web of Science ®Google Scholar
• Duncan CJ, Hambleton S. Varicella zoster virus immunity: A primer. J Infect. 2015;71(Suppl 1):S47–53.
   PubMedGoogle Scholar
• Kamiya H, Starr SE, Arbeter AM, et al. Antibody-dependent cell-mediated cytotoxicity against varicella-zoster virus-infected targets. Infect Immun. 1982;38:554–557.
   PubMed Web of Science ®Google Scholar
• Tilden AB, Cauda R, Grossi CE, et al. Demonstration of NK cell-mediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells. J Immunol. 1986;136:4243–4248.
   PubMed Web of Science ®Google Scholar
• Ito M, Bandyopadhyay S, Matsumoto-Kobayashi M, et al. Interleukin 2 enhances natural killing of varicella-zoster virus-infected targets. Clin Exp Immunol. 1986;65:182–189.
   PubMed Web of Science ®Google Scholar
• Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol. 2013;132: 515–525.
   PubMed Web of Science ®Google Scholar
• Fowler WJ, Garcia-Valcarcel M, Hill-Perkins MS, et al. Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus. Virology. 1995;214:531–540.
   PubMed Web of Science ®Google Scholar
• Haumont M, Jacquet A, Massaer M, et al. Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells. Virus Res. 1996;40:199–204.
   PubMed Web of Science ®Google Scholar
• Malavige GN, Jones L, Black AP, et al. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol. 2008;152:522–531.
   PubMed Web of Science ®Google Scholar
• Vafai A. Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine. Vaccine. 1995;13:1336–1338.
   PubMed Web of Science ®Google Scholar
• Berarducci B, Ikoma M, Stamatis S, et al. Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection. J Virol. 2006;80:9481–9496.
   PubMed Web of Science ®Google Scholar
• Berarducci B, Rajamani J, Zerboni L, et al. Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection. Proc Natl Acad Sci USA. 2010;107:282–287.
   PubMed Web of Science ®Google Scholar
• Mallory S, Sommer M, Arvin AM. Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. J Virol. 1997;71:8279–8288.
   PubMed Web of Science ®Google Scholar
• Hasan UA, Harper DR, Wren BW, et al. Immunization with a DNA vaccine expressing a truncated form of varicella zoster virus glycoprotein E. Vaccine. 2002;20:1308–1315.
   PubMed Web of Science ®Google Scholar
• Dendouga N, Fochesato M, Lockman L, et al. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012;30:3126–3135.
   PubMed Web of Science ®Google Scholar
• Fochesato M, Dendouga N, Boxus M. Comparative preclinical evaluation of as01 versus other adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine. Hum Vaccin Immunother. 2016;12:2092–2095.
   PubMed Web of Science ®Google Scholar
• Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200:337–346.
   PubMed Web of Science ®Google Scholar
• Garçon N, Di Pasquale A. From discovery to licensure, the adjuvant system story. Hum Vaccin Immunother. 2017;2(13):19–33.
   Google Scholar
• Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012;206:1280–1290.
   PubMed Web of Science ®Google Scholar
• Baldridge JR, McGowan P, Evans JT, et al. Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther. 2004;4:1129–1138.
   PubMed Web of Science ®Google Scholar
• Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines. 2011;10:471–486.
   PubMed Web of Science ®Google Scholar
• Detienne S, Welsby I, Collignon C, et al. Central role of CD169(+) lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01. Sci Rep. 2016;6:39475.
   PubMed Web of Science ®Google Scholar
• Welsby I, Detienne S, N’Kuli F, et al. Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21. Front Immunol. 2016;7:663.
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant as01 depends on activated dendritic cells. J Immunol. 2014;193:1920–1930.
   PubMed Web of Science ®Google Scholar
• Coccia M, Collignon C, Herve C, et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ Vaccines 2017;2:25.
   Web of Science ®Google Scholar
• Didierlaurent AM, Laupèze B, Di Pasquale A, et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16:55–63.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥50 years of age. J Infect Dis. 2013;208:1953–1961.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32:1745–1753.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Pauksens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34:863–868.
   PubMed Web of Science ®Google Scholar
• Lal H, Zahaf T, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (RZV): a phase-I, open-label study in Japanese adults. Hum Vaccin Immunother. 2013;9:1425–1429.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for industry for the evaluation of combination vaccines for preventable diseases: production, testing and clinical studies. U.S. Department of Health and Human Services, Food and Drug Administration: Center for Biologics Evaluation and Research; 1997.
   Google Scholar
• European Medicines Agency. Committee for medicinal products for human use. Guideline on clinical evaluation of new vaccines. London. [cited 2006 Oct 18]. (no. EMEA/CHMP/VWP/164653/2005).
   Google Scholar
• Tavares Da Silva F, Di Pasquale A, Yarzabal JP, et al. Safety assessment of adjuvanted vaccines: methodological considerations. Hum Vaccin Immunother. 2015;11:1814–1824.
   PubMed Web of Science ®Google Scholar
• Press release. GSK announces first approval of Shingrix in Canada. Media release. 13 October 2017.[cited 2017 Oct 20]. Available from https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-approval-of-shingrix-in-canada/
   Google Scholar
• Press release. Shingrix approved in the US for prevention of shingles in adults aged 50 and over. 23 October 2017. [cited 2017 Oct 26]. Available from https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-the-us-for-prevention-of-shingles-in-adults-aged-50-and-over/
   Google Scholar
• Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921–2929.
   PubMed Web of Science ®Google Scholar
• Berkowitz EM, Moyle G, Stellbrink H-J, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211:1279–1287.
   PubMed Web of Science ®Google Scholar
• Giordano G, Segal L, Prinsen M, et al. Non-clinical safety assessment of single and repeated administration of gE/AS01 zoster vaccine in rabbits. J Appl Toxicol. 2017;37:132–141.
   PubMed Web of Science ®Google Scholar
• Segal L, Thacker K, Fochesato M, et al. Intramuscularly administered herpes zoster subunit vaccine has no effects on fertility, pre- and post-natal development in Sprague-Dawley rats. Reprod Toxicol. 2017;69:297–307.
   PubMed Web of Science ®Google Scholar
• Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of the RZV adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live-attenuated herpes zoster vaccine. J Infect Dis. 2017; 216:1343–1351.
   Web of Science ®Google Scholar
• Marechal C, Lal H, Poder A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: a randomized trial. Vaccine. 2018;36:4278–4286.
   Google Scholar
• Pauksens K, Volpe S, Schwarz TF, et al. Persistence of immune response to an adjuvanted varicella‐zoster virus subunit candidate vaccine for up to year 9 in older adults. Open Forum Infect Dis. 2017;4(Suppl 1):S415.
   Google Scholar
• Di Pasquale A, Bonanni P, Garçon N, et al. Vaccine safety evaluation: practical aspects in assessing benefits and risks. Vaccine. 2016;34:6672–6680.
   PubMed Web of Science ®Google Scholar
• Tavares Da Silva F, De Keyser F, Lambert P-H, et al. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine. 2013;31:1870–1876.
   PubMed Web of Science ®Google Scholar
• Vink P, Shiramoto M, Ogawa M, et al. Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged >/=50 years when administered subcutaneously vs. intramuscularly. Hum Vaccin Immunother. 2017;13:574–578.
   PubMed Web of Science ®Google Scholar
• Poder A, Geeraerts B, Lal H, et al. Immunogenicity and safety of 2 doses of an investigational herpes zoster subunit vaccine administered 2, 6 or 12 months apart in adults 50 years and older: results of a phase III, randomized, open-label, multicenter trial. Open Forum Infect Dis. 2016;3(Suppl 1):753.
   Google Scholar
• Mols JF, Ledent E, Heineman TC. Sampling of herpes zoster skin lesion types and the impact on viral DNA detection. J Virol Meth. 2013;188:145–147.
   PubMed Web of Science ®Google Scholar
• Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004;5:344–356.
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Lal H, Cunningham A, et al. Efficacy, immunogenicity and safety of an investigational subunit adjuvanted herpes zoster vaccine in adults aged 60 years and older: results from the ZOE-50 and ZOE-70 efficacy studies. Open Forum Infect Dis. 2016;3(Suppl 1):127.
   Google Scholar
• de la Serna J, Campora L, Chandrasekar P, et al. Efficacy and safety of an adjuvanted herpes zoster subunit vaccine in autologous hematopoietic stem cell transplant recipients 18 years of age or older: first results of the phase 3 randomized, placebo-controlled ZOE-HSCT clinical trial. Abstract LBA2. BMT Tadem meetings; 2018 February 21-25; Utah, US. Available from: https://bmt.confex.com/tandem/2018/meetingapp.cgi/Paper/11724.
   Google Scholar
• Sullivan K, Abhyankar S, Campora L, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine in adult autologous hematopoietic stem cell transplant recipients: phase 3, randomized, placebo-controlled, ZOE-HSCT clinical trial. Abstract OS9-2. 44th Annual meeting of the European Society for Blood and Marrow Transplantation; March 18-21, 2018; Lisbon, Portugal.
   Google Scholar
• Schwarz T, Aggarwal N, Moeckesch B, et al. Randomized, phase III clinical trial to assess the immunogenicity and safety of an investigational subunit adjuvanted herpes zoster vaccine coadministered with a seasonal quadrivalent inactivated influenza vaccine in adults aged 50 years and older. Open Forum Infect Dis. 2016;3(Suppl 1):751.
   Google Scholar
• Shingrix Prescribing Information. [cited 2017 Nov 08]. Available from https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm581491.htm
   Google Scholar
• López-Fauqued M, Campora L, Delannois F, et al. Results of a safety pooled analysis of an adjuvanted herpes zoster subunit vaccine in more than 14,500 participants aged 50 years or older. Open Forum Infect Dis. 2017;4(Suppl 1):S416.
   Google Scholar
• Vink P. For the Zoster-028 study group. Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine in adults with solid tumors vaccinated before or during immunosuppressive chemotherapy treatment: a phase II/III, randomized clinical trial. Open Forum Infect Dis. 2017;4(Suppl 1):S417-S418.
   Google Scholar
• Oostvogels L. For the Zoster-039 study group. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults with hematologic malignancies: a phase III, randomized clinical trial. Open Forum Infect Dis. 2017;4(Suppl 1):S415.
   Google Scholar
• Vink P. For the Zoster-041 study group. Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine (HZ/su) in adults post renal transplant: a phase III randomized clinical trial. Open Forum Infect Dis. 2017;4(Suppl 1):S417.
   Google Scholar
• Centers for Disease Control and Prevention. Shingles (Herpes Zoster). [cited 2017 Jun 05]. Available from https://www.cdc.gov/shingles/hcp/clinical-overview.html#complications
   Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.
   PubMed Web of Science ®Google Scholar
• Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.
   PubMed Web of Science ®Google Scholar
• Mahamud A, Marin M, Nickell SP, et al. Herpes zoster-related deaths in the United States: validity of death certificates and mortality rates, 1979–2007. Clin Infect Dis. 2012;55:960–966.
   PubMed Web of Science ®Google Scholar
• Bricout H, Haugh M, Olatunde O, et al. Herpes zoster-associated mortality in Europe: a systematic review. BMC Public Health. 2015;15:466.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.
   PubMed Web of Science ®Google Scholar
• Drolet M, Levin MJ, Schmader KE, et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012;30:2047–2050.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, McGinnis JJ, Tan L, et al. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev. 2015;36:259–273.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, White R, O’Connor AB, et al. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc. 2007;55:1168–1175.
   PubMed Web of Science ®Google Scholar
• Varghese L, Nissen MD, Olivier A, et al. Public health perspective of phase III results of an investigational herpes zoster vaccine. Communicable Disease Control Conference 2015 June 1–2. Brisbane Australia. [cited 2017 May 06]. Available from https://www.phaa.net.au/eventsinfo/communicable-disease-control-conference-2.
   Google Scholar
• Van Oorschot D, Anastassopoulou A, Schlegel K, et al. The Public Health Impact Of A New Herpes Zoster Vaccine On The German Population. [cited 2017 May 05]. Available from: https://www.ispor.org/research_pdfs/54/pdffiles/PIH6.pdf
   Google Scholar
• Van Oorschot D, Tavares R, Varghese L, et al. Forecasting the potential public health impact of introducing a new herpes zoster vaccine to the Canadian population. Canadian Immunization Conference - 12th. 2016 December 7.
   Google Scholar
• Van Oorschot D, Hunjan E, Varghese L, et al. The Public Health Perspective Of An Investigational Herpes Zoster Vaccine In The United Kingdom (UK). [cited 2017 May 05]. Available from https://www.ispor.org/research_pdfs/54/pdffiles/PIH5.pdf
   Google Scholar
• Varghese L, Curran D, Yan S, et al. Estimating the potential public health impact of introducing the RZV vaccine in the US population aged ≥50 years. ID Week 2015. 2015 Oct 10.[cited 2017 May 02]. Available from: https://idsa.confex.com/idsa/2015/webprogram/Paper52887.html.
   Google Scholar
• Curran D, Van Oorschot D, Varghese L, et al. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccin Immunother. 2017;14:1–9.
   Google Scholar
• Cunningham AL, Garcon N, Leo O, et al. Vaccine development: from concept to early clinical testing. Vaccine. 2016;34:6655–6664.
   PubMed Web of Science ®Google Scholar
• Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22:1393–1398.
   PubMed Web of Science ®Google Scholar
• Preiss S, Garcon N, Cunningham AL, et al. Vaccine provision: delivering sustained & widespread use. Vaccine. 2016;34:6665–6671.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Marchant A, Levy J, et al. Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial. Clin Immunol. 2016;169:16–27.
   PubMed Web of Science ®Google Scholar
• Arnold N, Messaoudi I. Herpes zoster and the search for an effective vaccine. Clin Exp Immunol. 2017;187:82–92.
   PubMed Web of Science ®Google Scholar
• Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208:1375–1385.
   PubMed Web of Science ®Google Scholar